Latest Exclusive Distribution Agreements News

Sprintex Limited has inked an exclusive distribution agreement with ChoisTechnics Corp. to expand its hydrogen fuel cell compressor presence in South Korea, targeting key mobility and stationary markets.

Osteopore Limited has landed a two-year distribution deal for an innovative autologous dentin graft technology in Singapore, setting the stage for expansion across ASEAN and the wider Asia-Pacific dental market.

Jatcorp Limited reported a strong 36% revenue increase to $23 million for the half-year ended December 2025, narrowing its net loss and expanding its footprint across Asia Pacific markets despite ongoing legal challenges in China.

Audeara Limited reported a strong half-year revenue increase of 63.76% to $2.95 million, alongside a 57% reduction in net loss. However, the company flagged ongoing uncertainty about its ability to continue as a going concern.

RLF AgTech has secured strategic distribution partnerships with two leading Indian agricultural groups, marking its commercial entry into one of the world’s largest crop nutrition markets. These agreements position RLF for rapid expansion in India’s vast and growing agricultural sector.

Rhythm Biosciences has inked a non-exclusive distribution agreement with 4Cyte Pathology to integrate its ColoSTAT® colorectal cancer blood test into a vast pathology network across eastern Australia, aiming to boost adoption and accessibility.

Starpharma reports strong progress in strategic collaborations and internal drug development, alongside a 70% surge in Viraleze™ online sales and a solid $18.2 million cash position.

icetana Limited reported steady growth in Q2 FY26 with a 36% increase in annual recurring revenue and expanded partnerships across APAC and the Middle East. The company’s cash flow improved, while product enhancements aim to strengthen its AI security offerings.

Osteopore Limited has inked a three-year exclusive distribution agreement with MontsMed to introduce its advanced orthopaedic trauma reconstruction products into Hong Kong, positioning itself strategically within the Greater Bay Area.

Mastermyne Group has extended its exclusive distribution agreement with Jennmar Holdings for critical strata consolidation products by a decade, locking in supply until 2047. This move strengthens its foothold in the Australian underground coal mining sector.

Tetratherix has inked a global exclusive distribution agreement with healthcare giant Henry Schein, paving the way for its first bone regeneration product, Tegenix, to enter major markets in 2026. Concurrently, the company has begun building an advanced manufacturing facility to meet expected global demand.

Memphasys is intensifying its direct sales efforts for the Felix™ sperm-selection device across key Middle East IVF clinics, positioning for rapid market activation upon CE Mark approval expected early 2026.